A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: resembling (46)

Methotrexate ver 1

Description
Chemotherapy Protocol HEAD AND NECK CANCER METHOTREXATE Regimen Head and Neck Cancer – Methotrexate Indication Advanced head and neck cancer WHO Performance
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Methotrexate-ver-1.pdf

Cisplatin (100)-Radiotherapy

Description
Chemotherapy Protocol HEAD AND NECK CANCER CISPLATIN (100) RT Regimen Head and Neck Cancer – Cisplatin (100) RT Indication Radical treatment of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Cisplatin100-Radiotherapy.pdf

Cisplatin (100) RT (21 day)

Description
Chemotherapy Protocol HEAD AND NECK CANCER CISPLATIN (100) RT (21 day) Regimen Head and Neck Cancer – Cisplatin (100) RT (21 day
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Cisplatin-100-RT-21-day.pdf

HSCTRituximab_100mg-7day

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT RITUXIMAB 100mg (Weekly) Regimen • HSCT Allograft - Rituximab (7 day-100mg) Indications • EBV reactivation, PTLD and immune
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTRituximab-100mg-7day.pdf

Pentostatin

Description
Chemotherapy Protocol HAIRY CELL LEUKEMIA PENTOSTATIN Regimen • HCL – Pentostatin Indication • Hairy cell leukaemia Toxicity Drug Pentostatin Adverse Effect Myelosupression, rash, fever
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/HCL/Pentostatin.pdf

CladribineSC

Description
Chemotherapy Protocol HAIRY CELL LEUKEMIA CLADRIBINE (SC) Regimen • HCL – Cladribine (SC) Indication • Hairy cell leukemia Toxicity Drug Cladribine Adverse Effect Skin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/HCL/CladribineSC.pdf

CladribineIV

Description
Chemotherapy Protocol HAIRY CELL LEUKEMIA CLADRIBINE (IV-5 day) Regimen • HCL – Cladribine (IV-5 day) Indication • Hairy cell leukaemia (this is
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/HCL/CladribineIV.pdf

Bevacizumab ver 1

Description
Chemotherapy Protocol CNS CANCER BEVACIZUMAB This protocol may require funding. This is an unlicensed indication for bevacizumab. Regimen CNS-Bevacizumab Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CNS/Bevacizumab-ver-1.pdf

Papers Council of Governors - 26 January 2022

Description
Agenda attachments 1 CoG Agenda - 26.01.2022.docx Date Time Location Chair Agenda Council of Governors 26/01/2022 14:00 - 15:35 Microsoft Teams Peter Holli
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-26-January-2022.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8

Description
Chemotherapy Protocol Myeloma DVd (Weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (weekly)-Daratumumab-Dexamethasone Indication • Daratumumab in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf
291 to 300 of 757
Previous … 28 29 30 31 32 … Next